SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community discusses a potential short squeeze and references to the stock's historical volatility and meme status. A White House post mentioning "power to the players" has fueled speculation and excitement among investors. Comparisons to other meme stocks like BYND and AMC are prevalent, with some drawing parallels to past rallies.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

The Broke Coin community is rallying around the project's ongoing development and utility releases, emphasizing the team's dedication. Community members highlight the project's longevity and the team's active engagement as key differentiators in the meme coin space. The community is actively pushing for trending status, celebrating the coin's resilience within the Solana ecosystem.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is trending following news of a $150M oversubscribed registered direct offering, which the community believes will fuel capacity expansion and further growth in the photonics space; conversations revolve around the potential for this funding to drive increased production and the company's role in the AI infrastructure buildout. The offering is seen by some as a sign of strong institutional confidence and a catalyst for future profitability, while others express concerns about potential dilution despite the absence of warrants.

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics is trending due to strong earnings and revenue figures, along with analyst upgrades and maintained buy ratings. The community is discussing the company's focus on AI data centers, silicon photonics, and potential deals with European automakers amidst chip supply concerns. STM's advancements in edge AI, silicon carbide technology, and expansion into new markets also contribute to the increased interest.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending as traders discuss stablecoin regulations and USDC's role in the evolving digital economy. Community members are also closely monitoring USDC's adoption across different blockchains and its integration into various DeFi platforms. Several posts mention partnerships and integrations, as well as discussions on how USDC compares to other stablecoins.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amidst speculation of a potential acquisition of Warner Bros. Discovery ($WBD), with community chatter focusing on deal terms and potential impacts. Discussions involve potential partnerships with private equity firms like Apollo, and how a merger could reshape the media landscape, but also concerns about debt and potential overpayment. Some traders are looking ahead to subscriber growth driven by UFC streaming in 2026 as a major catalyst.

Futu Holdings Ltd. engages in the provision of digitalized financial services. It offers securities brokerage and wealth management products. The company was founded by Leaf Hua Li in December 2007 and is headquartered in Hong Kong.

Futu Holdings Ltd - ADR

FUTU is trending due to a mix of factors, including positive sentiment around Chinese ADRs and discussion of potential trade agreements between the U.S. and China. Bullish investors are actively debating the stock's valuation and potential for significant upside, while some are pointing to the stock's technical indicators and option activity.

Sonic is the highest-performing EVM L1, combining speed, incentives, and world-class infrastructure, powering the next generation of DeFi applications. The chain provides 400,000 TPS and sub-second finality.  Sonic's Fee Monetization (FeeM) program rewards developers with up to 90% of the fees their apps generate, adapting the Web2 ad-revenue model to a decentralized framework. Developers now directly profit from their app's traffic and user engagement.  Furthermore, the Sonic Gateway provides developers and users with seamless access to vast liquidity through a native, secure bridge connected to Ethereum. With a unique fail-safe mechanism, it ensures your assets are protected in all circumstances.

Sonic (prev. FTM)

The crypto, formerly known as FTM, is trending as the community discusses its recent Coinbase listing and name change to Sonic.  Community members are debating the token's potential, airdrop timing, and impact of the Sonic Summit. Some traders express frustration with the token's performance amidst broader discussions about the DeFi sector.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as the community discusses its potential for a significant move, citing its low market cap and circulating supply. Some users point to past cycles and potential exchange listings as catalysts, while others highlight its recent integration with Aleph Zero to enable fast, low-cost NFT minting and trading. The possibility of staking $RARI on KuCoin is also generating buzz.

SKALE is the world's fastest blockchain, designed for secure Ethereum scaling. SKALE Appchains provide ZERO gas fees to end-users and have advanced features such as AI/ML smart contracts, on-chain file storage, interchain messaging, and zero-cost minting. SKALE enables developers to deploy their own configurable EVM blockchain in minutes without sacrificing speed, security, or decentralization.

SKALE Network Coin

SKALE Network Coin is trending as the community discusses its potential, focusing on its low market cap and recent developments like the FAIR blockchain and partnerships. Speculation around AI integration and potential partnerships, possibly with Google Cloud, is also fueling interest.  Many are drawn to its zero gas fees and layer 1 development, envisioning significant long-term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aptevo Therapeutics (APVO) announced on Tuesday that a 100% remission rate was observed in a cohort of its Phase 1b/2 trial evaluating Mipletamig, in combination with Venetoclax and Azacitidine for newly diagnosed patients with acute myeloid leukemia (AML).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/mipletamig-delivers-100-remission-rate-cohort-3-rainier-trial">study</a> enrolled patients unfit for intensive chemotherapy. No dose-limiting toxicities or cytokine release syndrome were observed in the trial or among any frontline patients treated with Mipletamig to date, the company said.The 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy, the company said. It added that 40% of treated patients achieved minimal residual disease (MRD)-negative status, a critical marker of remission.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/APVO">APVO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels. Shares of the company traded 8% higher at the time of writing.<figure class="image"><img style="aspect-ratio:573/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_2_26_05_PM_png_6c3f4781c1.webp" alt="APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="573" height="61"><figcaption>APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed concerns about a potential dip in the share price.<stembedurl>https://stocktwits.com/WEL16/message/628866258</stembedurl>Another highlighted the drop in share price after the initial jump following the news.&nbsp;<stembedurl>https://stocktwits.com/Avior68/message/628866230</stembedurl>The company said that it is actively enrolling patients for the next cohort at the next dose levels and will present current findings at a medical conference in the last quarter.APVO stock is down by 98% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-fda-alleges-novo-nordisk-video-on-weight-loss-drugs-featuring-oprah-winfrey-is-false-or-misleading/chwyFEyRdzF">US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort

The company stated that the 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy.

Equity

Shares of Aptevo Therapeutics Inc. (APVO) rocketed 41% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-21-million-registered-direct-offering-and">said</a> it is looking to raise about $2.1 million in a registered direct offering and warrants sale.The company said it has entered into definitive securities purchase agreements for the purchase and sale of 1.76 million shares of its common stock in a registered direct offering and warrants to purchase up to 3.5 million shares of common stock in a concurrent private placement at a combined purchase price of $1.19 per share and accompanying warrant.The warrants will have an exercise price of $1.19 per share and will expire five years from the initial exercise date.The offering is expected to close on or about April 4.The company will use the net proceeds from the offering for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.On Stocktwits, retail investor sentiment about Aptevo jumped from ‘extremely bearish’ to ‘extremely bullish’ territory (97/100), hitting a one-year high. At the same time, message volume touched ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:652/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_11_35_45_AM_png_96a7494386.webp" alt="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK" width="652" height="153"><figcaption>APVO's Sentiment Meter and Message Volume as of 11:35 a.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the registered direct offering may be a “bailout” to institutions who were short.&nbsp;<stembedurl>https://stocktwits.com/leon_dedrick/message/610264441</stembedurl>Another user, however, expressed optimism about the share price rising to $3.<stembedurl>https://stocktwits.com/Bulltacos/message/610259261</stembedurl><a href="https://stocktwits.com/symbol/APVO">APVO shares</a> have lost over 55% this year and nearly all its value over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK">Trump’s Liberation Day Impact – Steel Stocks Tumble With Broader Market, UBS Flags Tariffs As 'Incremental Negative' For These Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail  Sentiment Touches Year-High

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in volatile trading.&nbsp;The stock drew significant heavy interest on Stocktwits, reaching the top 15 trending symbols list, where sentiment turned ‘extremely bullish’ amid a sharp rise in message volume.<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/APVO_sentiment_and_message_volume_on_Dec_12_f6c2ca53dd.png" alt="APVO sentiment and message volume on Dec 12.png" width="1314" height="320"><figcaption>APVO sentiment and message volume on Dec 12 as of 11:45 am ET | source: Stocktwits</figcaption></figure>The company announced that all patients with acute myeloid leukemia (AML) treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.&nbsp;This includes two patients who experienced complete remission with 100% cancer cell elimination.&nbsp;The trial is exploring mipletamig as frontline therapy in combination with venetoclax and azacitidine, the current standard of care for AML.Retail traders speculated heavily on the stock’s movements, attributing volatility to its small public float of around 500,000 shares.&nbsp;Optimistic users expressed confidence in the company’s long-term potential, with one noting that they had bought 1,000 shares of Aptevo.Aptevo’s oncology pipeline targets aggressive forms of cancer. Other highlights include:• ALG.APV-527: Currently in Phase 1 for 5T4-expressing solid tumors like breast, colon, and non-small cell lung cancers. Preliminary data presented at leading oncology conferences has been positive.• Other preclinical candidates, including APVO711 (immune checkpoint blockade and activator) and APVO603 (dual co-stimulatory solid tumor targeting), are designed for precision cancer treatments.Aptevo stock remains down over 96% year-to-date, reflecting other ongoing challenges. Its current market cap is just over $5 million.Still, retail investors remain cautiously optimistic for now as the company builds on promising clinical data while addressing broader market pressures.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish

The company announced that all patients with acute myeloid leukemia treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.

Why Aptevo Therapeutics Stock Is Cratering

Aptevo announced the pricing of a public offering of 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and warrants to purchase up to an aggregate of 6,800,000 shares of its...

Aptevo Therapeutics (NASDAQ:APVO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO - Free Report) in a research report report published on Tuesday morning. The brokerage issued a hold rating on the...

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO  Free Report) in a research note released on Sunday. The firm issued a hold rating on the biotechnology...

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...

Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?

Interim results from the Phase 1 trial of ALG.APV-527 by Alligator Bioscience and Aptevo Therapeutics. Positive signs of clinical activity in breast cancer patients, with well-tolerated treatment and...

Aptevo Therapeutics trading resumes

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Aptevo Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

APVO
Aptevo Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest APVO News

APVOAptevo Therapeutics Inc